1-6 of 6
Stephen T. Oh
Close
Sort by
Journal Articles

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Clinical Trials & Observations
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen T. Oh, Gary Schiller, James McCloskey, Jeanne Palmer, Houston Holmes, Steven Hager, Albert Assad, Susan Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1515–1528.
https://doi.org/10.1182/bloodadvances.2023011620
Published: 2024
Includes: Supplemental data
Journal Articles

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Clinical Trials & Observations
Stephen T. Oh, Ruben A. Mesa, Claire N. Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah A. Buckley, Shanthakumar Tyavanagimatt, Bryan G. Harder, Karisse Roman-Torres, Jennifer Smith, Adam R. Craig, John Mascarenhas, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5835–5842.
https://doi.org/10.1182/bloodadvances.2023010151
Published: 2023
Includes: Supplemental data
Journal Articles

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Clinical Trials & Observations
Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T. Oh, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron Gerds, Miklos Egyed, Jiří Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3582–3591.
https://doi.org/10.1182/bloodadvances.2022009311
Published: 2023
Includes: Supplemental data
Journal Articles

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

Tim Kong, Angelo B.A. Laranjeira, Taylor B. Collins, Elisa S. De Togni, Abigail J. Wong, Mary C. Fulbright, Marianna Ruzinova, Hamza Celik, Grant A. Challen, Daniel A.C. Fisher, Stephen T. Oh
Journal: Blood Advances
Blood Adv (2022) 6 (2): 611–623.
https://doi.org/10.1182/bloodadvances.2020002804
Published: 2022
Includes: Supplemental data
Journal Articles

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklos Egyed, Claire N. Harrison, Abdulraheem Yacoub, Alessandro Vannucchi, Adam J. Mead, Jean-Jacques Kiladjian, Jennifer O’Sullivan, Valentin García-Gutiérrez, Prithviraj Bose, Raajit K. Rampal, Carole B. Miller, Jeanne Palmer, Stephen T. Oh, Sarah A. Buckley, Diane R. Mould, Kaori Ito, Shanthakumar Tyavanagimatt, Jennifer A. Smith, Karisse Roman-Torres, Sri Devineni, Adam R. Craig, John O. Mascarenhas
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5825–5835.
https://doi.org/10.1182/bloodadvances.2020003314
Published: 2020
Includes: Supplemental data
Journal Articles

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Clinical Trials & Observations
Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark L. Heaney, Casey O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4282–4291.
https://doi.org/10.1182/bloodadvances.2020002662
Published: 2020
Includes: Supplemental data